|
1
|
Kalthoff H. How open is the therapeutic horizon for pancreatic cancer patients? Hepatobiliary Pancreat Dis Int 2022; 21:1-3. [PMID: 34789410 DOI: 10.1016/j.hbpd.2021.11.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 10/26/2021] [Indexed: 02/05/2023]
Affiliation(s)
- Holger Kalthoff
- Institute for Experimental Cancer Research, Christian-Albrechts-University, Kiel, Germany.
| |
Collapse
|
|
2
|
Malhotra P, Palanisamy R, Falasca M. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle. Hepatobiliary Pancreat Dis Int 2022; 21:4-6. [PMID: 34535394 DOI: 10.1016/j.hbpd.2021.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Accepted: 08/30/2021] [Indexed: 02/05/2023]
Affiliation(s)
- Pratibha Malhotra
- Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia
| | - Ranjith Palanisamy
- Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia
| | - Marco Falasca
- Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia.
| |
Collapse
|